Pharma major Lupin announced that it has received tentative approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%.

Lupin's Hydrocortisone Butyrate Lotion, 0.1% is the generic equivalent of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%. It is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximate USD 16.1 million in the US (IQVIA MAT October 2017).

Shares of the company gained Rs 18.4, or 2.24%, to settle at Rs 839.30. The total volume of shares traded was 124,365 at the BSE (Monday).